Irvine, CA – Exceltox, a CAP-accredited, CLIA-certified laboratory offering advanced clinical and toxicology testing, announced that it has now added pharmacogenomic testing to its list of services.
Research has shown that genetic factors may profoundly influence a person’s response to medications, including possible side effects. Physicians are increasingly relying on pharmacogenomic testing to help personalize treatment by predicting patient response.
Exceltox’s advanced pharmacogenomic testing technology can analyze structural changes in a gene’s DNA sequence to assess the influence of a drug in a particular patient. This empowers physicians to make optimized treatment decisions aimed at maximizing therapeutic benefits.
“Our pharmacogenomic testing allows physicians to prescribe the right drug and dosage early on, which can avoid an exhaustive, time-consuming process of treatment trial and error that may have negative effects or no benefit at all,” commented Exceltox Medical Director Todd A Glauser M.D., Ph.D.
Exceltox pharmacogenomic testing is currently available for use in the areas of pain management and mental health. For more information and for a comprehensive list of tests by drug type, please visit www.exceltox.com/pharmacogenomics.
